Thromboembolic Disease – Critical Evaluation of Laboratory Investigation

Summary

Previous studies of patients with thromboembolic disease have revealed an association either with hereditary anticoagulant protein deficiencies or with defects in the fibrinolytic system. To obtain a more comprehensive picture and to investigate which analyses are useful in the evaluation of such patients, we have performed an extensive laboratory investigation in 439 individuals with thromboembolic disease. Anticoagulant protein deficiencies were found in 24 patients. Deficiencies of protein C (n = 10) and protein S (n = 9) were most common followed by deficiencies of antithrombin III (n = 3) and plasminogen (n = 2). Six of the nine protein S deficient patients demonstrated a selective deficiency of free protein S with normal total protein S concentrations. To diagnose protein C and S deficiencies among the 201 patients receiving oral vitamin K antagonists, the concentrations of protein C and S were compared with the mean concentration of several other vitamin K-dependent proteins. One protein C and three protein S deficiencies were identified among the treated patients. The number of protein C deficiencies found in this group was significantly lower than the number found among untreated patients. Although fewer protein S deficiencies were also identified among the treated patients, than in the untreated group, the difference was not statistically significant. The results suggest that protein C deficiencies went undetected in the treated group and that oral anticoagulant therapy should be discontinued before efforts to diagnose protein C deficiency are made. We found no cases with heparin cofactor II deficiency. Lupus anticoagulant was present in 10 patients. Evaluation of the fibrinolytic system revealed that the patient group had slightly lower mean euglobulin fibrinolytic activity (EFA) after venous occlusion than controls and a subgroup (approximately 15%) of patients with EFA below the level of the 5th percentile of controls, could be distinguished. Repeated analysis demonstrated a substantial individual day-to-day variation in both patients and controls and the combined EFA results did not clearly distinguish patients from controls. There was a significant negative correlation between EFA and plasminogen activator inhibitor (PAI) levels in both patients and controls and the patient group had significantly higher levels of PAI than the control group. In contrast, there was no difference between controls and patients in tissue plasminogen activator (tPA) release after venous occlusion and no correlation between EFA and tPA was observed. These results suggest that although a statistically significant difference between patients and controls in values of fibrinolytic parameters was found, an extensive laboratory evaluation of the fibrinolytic system in individual patients may not be warranted. The association between patients with thrombosis and deficiencies of anticoagulant proteins suggests that the investigation of individual patients should focus on these components.

• References

• 1 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
• 2 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121-1125
• 3 van Hinsbergh VWM, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
• 4 de Fouw NJ, Haverkate F, Bertina RM, Koopman J, van Wijngaarden A, van Hinsbergh VWM. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. Blood 1986; 4: 1189-1192
• 5 Walker FJ. Protein S and the regulation of activated protein C. Semin Thromb Hemostas 1984; 10: 131-138
• 6 Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement protein C4b-binding protein. Proc Natl Acad Sci USA 1981; 78: 2512-2516
• 7 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088
• 8 Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022-12027
• 9 Griffin JH, Evatt B, Zimmerman T, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 10 Schwartz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300
• 11 Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-508
• 12 Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diathes Haemorrh 1965; 13: 516-530
• 13 von Kaulla E, von Kaulla KN. Deficiency of antithrombin III activity associated with hereditary thrombosis tendency. J Med 1972; 3: 349-358
• 14 van den Meer J, Stoepman-van Dalen EA, Jansen JMS. Antithrombin III deficiency in a Dutch family. J Clin Pathol 1973; 26: 532-538
• 15 Sas G, Blasko G, Banhegyi D, Jako J, Palos LA. Abnormal antithrombin III (antithrombin III “Budapest”) as a cause of familial thrombophilia. Thromb Diathes Haemorrh 1974; 32: 1205-1215
• 16 Tran TH, Bondeli C, Marber GA, Duckert F. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa. Thromb Haemostas 1980; 44: 92-95
• 17 Tollefsen DM, Blank M. Detection of a new heparin – dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 18 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet 1985; ii: 413-414
• 19 Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; ii: 414-416
• 20 Bithell TC. Hereditary dysfibrinogenemia. Clin Chem 1985; 31: 509-516
• 21 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis, a study of 25 cases and a review of the literature. Haemostasis 1985; 15: 254-262
• 22 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
• 23 Browse NL, Gray L, Jarrett PEM, Morland M. Blood and vein-wall fibrinolytic activity in health and vascular disease. Br Med J 1977; 1: 478-481
• 24 Nilsson IM, Ljungnér H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activation inhibitor. Br Med J 1985; 290: 1453-1456
• 25 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holroet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
• 26 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep venous thrombosis. J Lab Clin Med 1985; 105: 265-270
• 27 Aoki N, Moroi M, Sakata Y, Yoshida N. Abnormal plasminogen, a hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978; 61: 1186-1195
• 28 Scharrer IM, Wohl RC, Hach V, Sinio L, Boreisha I, Robbins KC. Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis. Thromb Haemostas 1986; 55: 396-401
• 29 Nilsson IM. Haemorrhagic and Thrombotic Diseases. John Wiley & Sons; London: 1974
• 30 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29 (suppl. 124) 21-37
• 31 Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-443
• 32 Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5
• 33 Bertina RM, Broekmans AW, Reinalda-Poot S, Poort SR, Bom VJJ. Determination of plasma protein S – the protein cofactor of activated protein C. Thromb Haemostas 1985; 53: 268-272
• 34 Tran TH, Duckert F. Heparin cofactor II determination – levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Thromb Haemostas 1984; 52 (2) 112-116
• 35 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
• 36 Stavenow L, Mattiasson I, Theodorsson B, Hood B. Spontaneous efflux of platelet α-granule components in relation to ¹⁴C-norepi-nephrine in buffers. Life Sci 1982; 30: 1899-905
• 37 Robertson BR, Pandolfi M, Nilsson IM. “Fibrinolytic activity” in healthy volunteers as estimated from effect of venous occlusion of arms. Acta Chir Scand 1972; 138: 429-436
• 38 Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266
• 39 Heijboer H, Brandjes DPM, Büller MR, Sturk A, Ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 232: 1512-1516
• 40 Taberno MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-254
• 41 Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemostas 1988; 59: 18-22
• 42 Broekmans AW, van der Linden IK, Jansen-Koeter Y, Bertina RM. Prevalence of protein C (PC) and protein S (PS) deficiency in patients with thrombotic disease. Thromb Res 1986; suppl. VI: 135 (Abstr.)
• 43 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
• 44 Iijima K, Inone N, Nakamura K, Fukuda C, Ohgi S, Okada M, Mori T, Nishioka J, Hayashi T, Suzuki K. Inherited deficiency of functional and free form protein S. Acta Haematol Jpn 1989; 52: 126-133
• 45 Vikydal R, Korninger C, Kyrle PA, Niessner H, Pabinger I, Thaler E, Lechner K. The prevalence of hereditary antithrombin-III deficiency in patients with a history of venous thromboembolism. Thromb Haemostas 1985; 54: 744-745
• 46 Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJP. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200
• 47 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 1221-1228
• 48 Aznar J, Dasi A, Espana F, Estelles A. Fibrinolytic study in a homozygous protein C deficient patient. Thromb Res 1986; 42: 313-322
• 49 Conard J, Horellou MH, Teger-Nilsson AC, Bertina RM, Samama M. The fibrinolytic system in patients with congenital protein C deficiency. Thromb Res 1984; 36: 363-367
• 50 Engesser L, Brommer EJP, Kluft C, Briët E. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? – A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemostas 1989; 62: 673-680
• 51 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387